Bayer signs grant agreement to advance innovation in non-hormonal contraception
Friday, October 21, 2022
Bayer has announced that it received a grant from the Bill & Melinda Gates Foundation to co-fund pre-clinical research activities aimed at providing women globally with a non-hormonal contraceptive option. The grant involves a commitment of over US$ 12 million from both Bayer and the Gates Foundation over four years. Bayer will utilize its expertise in women's healthcare and research and development to identify a pre-clinical development candidate, with the commitment to make the product available at an affordable price in low- and lower-middle-income countries upon approval by health authorities. The collaboration aligns with Bayer's focus on sustainability and its goal of providing innovative non-hormonal contraceptive options to girls and women worldwide. The partnership aims to address gender inequality, teenage pregnancy, and maternal health concerns by expanding access to modern contraception, empowering women, and supporting their educational and employment opportunities. This initiative builds upon Bayer's long-standing commitment to women's health and its efforts to make modern contraception accessible globally.
